Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Trials in Progress: A Phase I Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants with Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High-Risk Myelodysplastic Syndrome

Lina Benajiba, MD PhD, Hetty E. Carraway, MD MBA, Nada Hamad, MB.BS, FRACP, FRCPA, Eytan M. Stein, MD, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Amy Burroughs, Scott Harris, Hayley Lane, Dorothy D. Nguyen, MD, Monic Stuart, MD MPH, Jesse Vargas, PhD, Alexandre Puissant, PhD, Kimberly Stegmaier, MD, Courtney D. DiNardo, MD MSCE

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-140636

Published: 2020

Journal Articles

Niche-like Ex Vivo High Throughput (NEXT) Drug Screening Platform in Acute Myeloid Leukemia

Reinaldo Dal Bello Figueiras, MD, Justine Pasanisi, Romane Joudinaud, Matthieu Duchmann, Gaetano Sodaro, Clementine Chauvel, Loic Vasseur, MD, Bryann Pardieu, Frank Ling, Kim Pacchiardi, Camille Vaganay, Lionel Faivre, Chaïma Benaksas, Claude Preudhomme, MD PhD, Emmanuel Raffoux, MD, Emmanuelle Clappier, PhD PharmD, Lionel Ades, MDPhD, Alexandre Puissant, PhD, Raphael Itzykson, MD PhD

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-137048

Published: 2020

Journal Articles

The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies

Blood (2019) 134 (Supplement_1): 877.

https://doi.org/10.1182/blood-2019-131255

Published: 2019

Journal Articles

Targeting the Creatine Kinase Pathway in EVI1-Positive Acute Myeloid Leukemia

Alexandre Puissant, PhD, Nina Fenouille, PhD, Christopher F. Bassil, BA, Issam Ben-Sahra, PhD, Lina Benajiba, Gabriela Alexe, PhD, Azucena Ramos, Yana Pikman, MD, Michael R. Burgess, MD PhD, Qing Li, MD PhD, Frederic Luciano, PhD, Patrick Auberger, PhD, Ilene Galinsky, MSN, ANPc, Daniel J. DeAngelo, MD PhD, Richard M. Stone, MD, Archibald S. Perkins, MD PhD, Kevin Shannon, MD, Michael T. Hemann, PhD, Kimberly Stegmaier, MD

Blood (2016) 128 (22): 523.

https://doi.org/10.1182/blood.V128.22.523.523

Published: 2016

Journal Articles

Identification of CKMT1B As a New Target in EVI1-Positive AML

Alexandre Puissant, PhD, Nina Fenouille, PhD, Christopher F. Bassil, BA, Issam Ben-Sahra, PhD, Gabriela Alexe, PhD, Lina Benajiba, Azucena Ramos, Yana Pikman, MD, Michael R. Burgess, MD PhD, Ilene Galinsky, ANP, Daniel J. DeAngelo, MD PhD, Richard M. Stone, MD, Kevin Shannon, MD, Michael T. Hemann, PhD, Kimberly Stegmaier, MD

Blood (2015) 126 (23): 3674.

https://doi.org/10.1182/blood.V126.23.3674.3674

Published: 2015

Journal Articles

Targeting MTHFD2 in Acute Myeloid Leukemia

Yana Pikman, MD, Alexandre Puissant, PhD, Gabriela Alexe, PhD, Andrew Furman, BA, Stacey Frumm, BA, Linda Ross, PhD, Liying Chen, PhD, Nina Fenouille, PhD, Christopher F. Bassil, BA, Caroline A Lewis, PhD, Richard M. Stone, MD, Daniel J. DeAngelo, MD PhD, Ilene Galinsky, ANP, Andrew L Kung, MD PhD, Matthew Vader Heiden, MD PhD, Michael T. Hemann, PhD, Versha Banerji, MD, Kimberly Stegmaier, MD

Blood (2015) 126 (23): 443.

https://doi.org/10.1182/blood.V126.23.443.443

Published: 2015

Journal Articles

Targeting Folate Metabolism In Acute Myelogenous Leukemia

Yana Pikman, MD, Alexandre Puissant, PhD, Gabriela Alexe, PhD, Stacey M. Frumm, Linda Ross, PhD, Liying Chen, Ph.D., Nina Fenouille, PhD, Christopher F Bassil, Clary B. Clish, PhD, Andrew L Kung, MD, PhD, Michael T Hemann, PhD, Versha Banerji, MD, Kimberly Stegmaier, MD

Blood (2013) 122 (21): 3798.

https://doi.org/10.1182/blood.V122.21.3798.3798

Published: 2013

NARROW

Trials in Progress: A Phase I Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants with Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High-Risk Myelodysplastic Syndrome

Niche-like Ex Vivo High Throughput (NEXT) Drug Screening Platform in Acute Myeloid Leukemia

The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies

Targeting the Creatine Kinase Pathway in EVI1-Positive Acute Myeloid Leukemia

Identification of CKMT1B As a New Target in EVI1-Positive AML

Targeting MTHFD2 in Acute Myeloid Leukemia

Targeting Folate Metabolism In Acute Myelogenous Leukemia

Email alerts

ASH Publications

American Society of Hematology

Trials in Progress: A Phase I Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants with Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High-Risk Myelodysplastic Syndrome

Niche-like Ex Vivo High Throughput (NEXT) Drug Screening Platform in Acute Myeloid Leukemia

The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies

Targeting the Creatine Kinase Pathway in EVI1-Positive Acute Myeloid Leukemia

Identification of CKMT1B As a New Target in EVI1-Positive AML

Targeting MTHFD2 in Acute Myeloid Leukemia

Targeting Folate Metabolism In Acute Myelogenous Leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only